Two stocks in Healthcare
Gerresheimer vs Lonza Group: profit, growth, debt and price compared
Lonza Group is stronger on 5 of 6 figures: profit margin, sales growth, debt, analysts' view and price trend. Gerresheimer is stronger on 1: price for its expected profit.
Save both stocks to your watchlist and revisit their latest fundamentals.
| GerresheimerGXI.DE | Lonza GroupLONN.SW | |
|---|---|---|
| Net margin | −17.5% | Stronger: −1.6% |
| Revenue growth, past year | −0.80% | Stronger: +11.20% |
| Debt to equity | 236.7% | Stronger: 51.1% |
| Forward P/E | Stronger: 13.5× | 29.7× |
| Dividend yield | — | 0.75% |
| Analysts | Hold · 12 | Stronger: Buy · 23 |
| From its 200-day average | +13.7% | Stronger: +17.8% |
Share price over the past year
- Gerresheimer+40.9%
- Lonza Group+25.8%
20 Nov 202518 Nov 2026
Gerresheimer or Lonza Group: which is stronger?
- LONN.SW
Which is more profitable?
Lonza Group keeps more of each sale as profit: −1.6% against −17.5%.
- LONN.SW
Which is growing its sales faster?
Lonza Group is growing its sales faster: +11.20% over the past year, against −0.80%.
- LONN.SW
Which has borrowed less?
Lonza Group has borrowed less: its debt is 51.1% of what its shareholders own, against 236.7% for Gerresheimer.
- GXI.DE
Which costs less for the profit it is expected to make?
Gerresheimer costs less for the profit it is expected to make: 13.5× its forward earnings, against 29.7×.
Which pays more in dividends?
Lonza Group pays 0.75% a year in dividends for what a share costs, where Gerresheimer pays none.
- LONN.SW
Which do analysts rate higher?
Analysts are warmer on Lonza Group: Buy, against Hold for Gerresheimer.
- LONN.SW
Which is in the stronger price trend?
Lonza Group's price is in the stronger trend: 17.8% above its 200-day average, against 13.7% above.
What each company does
GXI.DEGerresheimer
Gerresheimer AG, together with its subsidiaries, provides drug containment solutions in Germany and internationally.
Reports results on 25 November 2026
LONN.SWLonza Group
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, and internationally.
Reports results on 27 January 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.